[{"data":1,"prerenderedAt":260},["ShallowReactive",2],{"drug-warfarin":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":19,"formulations":23,"regimens":101,"contraindications":136,"warnings":146,"renal":147,"monitoring":148,"interactions":149,"review":150,"examples":153,"atc":154,"iran":156,"links":196,"populations":213,"usApproval":255},"warfarin",1,{"fa":7,"en":8},"وارفارین","Warfarin","blood",{"fa":11,"en":12},"آنتاگونیست ویتامین K","Vitamin K antagonist",[14,17],{"name":15,"market":16},"Coumadin","US",{"name":18,"market":16},"Jantoven",[20,21,7,22],"coumadin","کومادین","INR",[24,37,45,53,61,69,77,85,93],{"id":25,"form":26,"route":27,"label":28,"concentration":29,"markets":32,"refs":33},"tab-1","tablet","oral","1 mg tablet (scored)",{"amount":5,"unit":30,"perUnit":26,"scored":31},"mg",true,[16],[34],{"source":35,"section":36},"fda-warfarin","3",{"id":38,"form":26,"route":27,"label":39,"concentration":40,"markets":42,"refs":43},"tab-2","2 mg tablet (scored)",{"amount":41,"unit":30,"perUnit":26,"scored":31},2,[16],[44],{"source":35,"section":36},{"id":46,"form":26,"route":27,"label":47,"concentration":48,"markets":50,"refs":51},"tab-2-5","2.5 mg tablet (scored)",{"amount":49,"unit":30,"perUnit":26,"scored":31},2.5,[16],[52],{"source":35,"section":36},{"id":54,"form":26,"route":27,"label":55,"concentration":56,"markets":58,"refs":59},"tab-3","3 mg tablet (scored)",{"amount":57,"unit":30,"perUnit":26,"scored":31},3,[16],[60],{"source":35,"section":36},{"id":62,"form":26,"route":27,"label":63,"concentration":64,"markets":66,"refs":67},"tab-4","4 mg tablet (scored)",{"amount":65,"unit":30,"perUnit":26,"scored":31},4,[16],[68],{"source":35,"section":36},{"id":70,"form":26,"route":27,"label":71,"concentration":72,"markets":74,"refs":75},"tab-5","5 mg tablet (scored)",{"amount":73,"unit":30,"perUnit":26,"scored":31},5,[16],[76],{"source":35,"section":36},{"id":78,"form":26,"route":27,"label":79,"concentration":80,"markets":82,"refs":83},"tab-6","6 mg tablet (scored)",{"amount":81,"unit":30,"perUnit":26,"scored":31},6,[16],[84],{"source":35,"section":36},{"id":86,"form":26,"route":27,"label":87,"concentration":88,"markets":90,"refs":91},"tab-7-5","7.5 mg tablet (scored)",{"amount":89,"unit":30,"perUnit":26,"scored":31},7.5,[16],[92],{"source":35,"section":36},{"id":94,"form":26,"route":27,"label":95,"concentration":96,"markets":98,"refs":99},"tab-10","10 mg tablet (scored)",{"amount":97,"unit":30,"perUnit":26,"scored":31},10,[16],[100],{"source":35,"section":36},[102,122],{"id":103,"disease":104,"label":105,"population":108,"type":112,"unit":30,"dose":113,"refs":117},"af","atrial-fibrillation",{"fa":106,"en":107},"ضدانعقاد خوراکی — بر اساس INR","Oral anticoagulation — INR-guided",{"minAge":109},{"value":110,"unit":111},18,"year","notCalculated",{"reason":114},{"fa":115,"en":116},"دوز فردی و بر اساس INR. اگر ژنوتیپ نامعلوم است، شروع معمول ۲ تا ۵ mg یک بار در روز؛ AF غیردریچه‌ای: هدف INR ۲٫۵ (۲ تا ۳).","Individualised, INR-guided. If genotype unknown, usual start 2–5 mg once daily; non-valvular AF: target INR 2.5 (2.0–3.0).",[118,120],{"source":35,"section":119},"2.3",{"source":35,"section":121},"2",{"id":123,"disease":104,"label":124,"population":127,"type":112,"unit":30,"dose":129,"refs":133},"peds",{"fa":125,"en":126},"کودکان","Children",{"maxAge":128},{"value":110,"unit":111},{"reason":130},{"fa":131,"en":132},"مطالعه کنترل‌شده در کودکان نیست؛ دوز بهینه نامعلوم.","No controlled pediatric studies; optimum dosing unknown.",[134],{"source":35,"section":135},"8.4",[137],{"id":138,"severity":139,"text":140,"refs":143},"ci","block",{"fa":141,"en":142},"بارداری (جز دریچه مکانیکی پرخطر)؛ تمایل به خونریزی یا دیسکرازی خونی؛ جراحی اخیر یا برنامه‌ریزی‌شده CNS یا چشم (و سایر موارد بخش ۴).","Pregnancy (except high-risk mechanical valves); haemorrhagic tendencies or blood dyscrasias; recent or planned CNS or eye surgery (and other items in section 4).",[144],{"source":35,"section":145},"4",[],[],[],[],{"status":151,"reviewer":152,"date":152},"unverified",null,[],[155],"B01AA03",{"status":157,"forms":158,"refs":191},"registered",[159,163,167,171,175,179,183,187],{"code":160,"en":161,"fa":162},"12117","WARFARIN SODIUM 0.5MG TAB","قرص وارفارین سدیم ۰٫۵ میلی‌گرم",{"code":164,"en":165,"fa":166},"08024","WARFARIN SODIUM 1MG TAB","قرص وارفارین سدیم ۱ میلی‌گرم",{"code":168,"en":169,"fa":170},"02199","WARFARIN SODIUM 2.5MG TAB","قرص وارفارین سدیم ۲٫۵ میلی‌گرم",{"code":172,"en":173,"fa":174},"12575","WARFARIN SODIUM 2MG  TAB","قرص وارفارین سدیم ۲ میلی‌گرم",{"code":176,"en":177,"fa":178},"10097","WARFARIN SODIUM 3MG TAB","قرص وارفارین سدیم ۳ میلی‌گرم",{"code":180,"en":181,"fa":182},"12569","WARFARIN SODIUM 4MG  TAB","قرص وارفارین سدیم ۴ میلی‌گرم",{"code":184,"en":185,"fa":186},"01309","WARFARIN SODIUM 5MG TAB","قرص وارفارین سدیم ۵ میلی‌گرم",{"code":188,"en":189,"fa":190},"12570","WARFARIN SODIUM 6MG  TAB","قرص وارفارین سدیم ۶ میلی‌گرم",[192],{"source":193,"section":194,"url":195},"darooyab-generic","G-1932\u002FWarfarin","https:\u002F\u002Fwww.darooyab.ir\u002FG-1932\u002FWarfarin",[197,201,205,208,211],{"kind":198,"url":199,"label":200},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=040301","ANDA040301",{"kind":202,"url":203,"label":204},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=cdbbc317-35d3-42ba-94f0-c83891358529","FDA Warfarin",{"kind":206,"url":207,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa682277.html",{"kind":209,"url":210,"label":155},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=B01AA03",{"kind":212,"url":195,"label":8},"darooyab",{"pregnancy":214,"lactation":222,"pediatric":231,"geriatric":239,"reproductive":247},{"level":215,"text":216,"quote":219,"refs":220},"contraindicated",{"fa":217,"en":218},"برچسب: در بارداری منع مصرف دارد.","Label: contraindicated in pregnancy.","Warfarin sodium tablets, USP are contraindicated in: • Pregnancy Warfarin sodium tablets, USP are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions (5.7) and Use in Specific Populations (8.1) ].",[221],{"source":35,"section":145},{"level":223,"text":224,"quote":227,"refs":228},"caution",{"fa":225,"en":226},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Warfarin was not present in human milk from mothers treated with warfarin from a limited published study.",[229],{"source":35,"section":230},"8.2",{"level":232,"text":233,"quote":236,"refs":237},"not-established",{"fa":234,"en":235},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Adequate and well-controlled studies with warfarin sodium have not been conducted in any pediatric population, and the optimum dosing, safety, and efficacy in pediatric patients is unknown.",[238],{"source":35,"section":135},{"level":223,"text":240,"quote":243,"refs":244},{"fa":241,"en":242},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Conduct more frequent monitoring for bleeding with administration of warfarin sodium to elderly patients in any situation or with any physical condition where added risk of hemorrhage is present.",[245],{"source":35,"section":246},"8.5",{"level":223,"text":248,"quote":251,"refs":252},{"fa":249,"en":250},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Females Advise females of reproductive potential to use effective contraception during treatment and for at least 1 month after the final dose of warfarin sodium.",[253],{"source":35,"section":254},"8.3",{"kind":256,"refs":257,"id":200},"ANDA",[258],{"source":35,"section":259},"SPL approval \u002F marketing category",1792191866226]